Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Plavix

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Plavix was produced by Sanofi and Bristol-Myers Squibb.

AZ's Brilinta disappoints in stroke trial

AZ's Brilinta disappoints in stroke trial

superiority to Sanofi's Plavix (clopidogrel), a former blockbuster now subject to generic competition.

FDA gives the nod to TMC's antiplatelet drug

FDA gives the nod to TMC's antiplatelet drug into a market formerly dominated by Sanofi's Plavix (clopidogrel) which lost patent protection in 2012. ... In a trial that compared Kengreal to Plavix in more than 10, 000 participants, TMC's significantly reduced the occurrence of heart attack, the

Heart drug sales continue downward spiral

Heart drug sales continue downward spiral Sanofi has a number of CV medicines including Aprovel (irbesartan), Lovenox (enoxaparin) and the co-marketed Plavix (clopidogrel), which collectively made the firm 4.2bn euro ($4.7bn) last year, helping

FDA reviewer backs approval of TMC's cangrelor

FDA reviewer backs approval of TMC's cangrelor Claims it offers a small benefit over Sanofi’s Plavix.  . The Medicines Company (TMC) looks on course finally to get approval for its intravenous antiplatelet drug cangrelor in the US after ... the multibillion-dollar market formerly occupied by Sanofi

AZ’s Brilinta clears cardiovascular outcomes trial

AZ’s Brilinta clears cardiovascular outcomes trial Brilinta was first launched in 2011 as potential successor to Sanofi's formerly $7bn-a-year antiplatelet brand Plavix (clopidogrel), which saw its sales decimated by generic competition after key patents

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...

Infographics